Clinical trials: Early Parkinson Disease (Early PD)
Early Stage Non-small Cell Lung Cancer
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT04530227
- Testing
- Biological: Camrelizumab, Pemetrexed, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Parkinson's Disease, DBS
Prospective Study to Compare Results of STN-DBS Between Early Treated and Late-treated PD Patient
The aim of this study is to investigate the impact of DBS not only no motor outcomes, but also on neuropsychological and psychiatric aspects and on quality of life in young patients with a short history of disease.
- Conditions
- Parkinson's Disease, DBS, Deep Brain Stimulation, STN
- Trial name
- DeBraStE (NCT01274832)
- Testing
- Deep Brain Stimulation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson Disease
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
- Trial name
- NCT04571164
- Testing
- LY03003(Rotigotine,extended-release microspheres)
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
TMS Protocols in the Treatment of PD
Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment
The goal of this study is to determine whether transcranial magnetic stimulation (TMS) is an effective treatment in Parkinson's disease patients with depression or cognitive impairment.
- Trial name
- NCT03552861
- Testing
- repetitive transcranial magnetic stimulation(rTMS)
- Where
- 10 sites in China
- Volunteers
- 252 people
- Sponsor
- Guangdong Provincial People's Hospital
Parkinson Disease
Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease
Pre-Active PD is a randomized controlled feasibility study to evaluate the implementation of a telehealth-delivered physical activity behavior change intervention for people with early-mid stage Parkinson's disease.
- Trial name
- NCT05308238
- Testing
- Occupational therapy intervention group, Disease management education group
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- San Jose State University
Parkinson Disease, Progression, Disease
Neuromelanin MRI: A Progression Marker in Early PD
Prospective observational study to qualify NM-MRI as progression marker in early Parkinson's.
- Trial name
- InsIghtPD (NCT05631158)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Parkinson Disease
Early Versus Late Application of STN DBS to PD Patients With Motor Complications
Although deep brain stimulation of the subthalamic nucleus(STN DBS) has become the surgical treatment of choice for Parkinson's disease(PD), a consensus on the timing of surgery is lacking.
- Trial name
- ELASS (NCT01922388)
- Testing
- Bilateral deep brain stimulation of the subthalamic nucleus
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Ling
Parkinson's Disease
Early Parkinson's Disease (PD) Cross-Sectional
Purpose: 1. To see if cytokine levels and oligomeric alpha-synuclein levels in blood and cerebrospinal fluid could be used as biological markers for Parkinson's disease (PD) onset and progression. 2.
- Trial name
- EPDX (NCT00817453)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Very Early Stage of Parkinson's Disease
Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)
Parkinson's disease has only pharmacological (essentially dopaminergic) and surgical treatment (essentially high-frequency deep brain stimulation), that are symptomatically effective.
- Trial name
- Ev-NIRT (NCT04261569)
- Testing
- Ev-NIRT
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Grenoble
Breast Neoplasms, Triple Negative Breast Neoplasms
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Researchers are looking for new ways to treat types of breast cancer that are both: High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment Early-stage, which means the cancer is…
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
- Trial name
- NCT06966700
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 331 sites in United States, Argentina and 39 more
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease, Idiopathic
Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients
This study is a randomized, double-blind, controlled trial exploring the effects of long-term taVNS intervention in patients with early-stage Parkinson's disease.
- Trial name
- NLTVNSPD (NCT06665113)
- Testing
- taVNS real stimulation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Kezhong Zhang
Parkinson's Disease (PD)
Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease
The objective of this observational study is to investigate whether non-invasive fundus retinal detection technology can be used for the early diagnosis of parkinson's disease (PD).
- Trial name
- NCT07244640
- Testing
- non-invasive fundus retinal detection
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Parkinson's Disease
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
- Trial name
- NCT00203060
- Testing
- Rasagiline Mesylate
- Volunteers
- 404 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinson's Disease
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS).
- Trial name
- CONFIDENT-PD (NCT01060878)
- Testing
- PYM50028
- Where
- 111 sites in United States, Canada and 8 more
- Volunteers
- 425 people
- Sponsor
- Phytopharm
Parkinson's Disease
MIRT and Rotigotine in the Early Stage of PD
To test whether a multidisciplinary intensive rehabilitation treatment (MIRT) slowed down the progression of the disease in Parkinson's disease (PD) "de novo" patients, all treated with Rotigotine, in a randomized controlled…
- Trial name
- MIRT-RT (NCT02100176)
- Testing
- Multidisciplinary intensive rehabilitation treatment, Rotigotine
- Where
- 2 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Parkinson's Disease
Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications.
- Trial name
- NCT00282152
- Testing
- B-STN DBS, Optimal drug therapy
- Volunteers
- 37 people
- Sponsor
- Vanderbilt University Medical Center
Parkinson's Disease
Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease…
- Trial name
- NCT04536857
- Testing
- Biomarker assay
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Huashan Hospital